Immage Biotherapeutics Corp.
IMMG
$0.00
$0.000.00%
OTC PK
| 02/28/2017 | 11/30/2016 | 08/31/2016 | 05/31/2016 | 02/29/2016 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.03% | 37.95% | 30.00% | 179.59% | 1,838.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.64% | 4,932.83% | 82.35% | 246.26% | 3,766.67% |
| Operating Income | 36.64% | -4,932.83% | -82.35% | -246.26% | -3,766.67% |
| Income Before Tax | 36.64% | -4,814.41% | -82.35% | -246.26% | -3,766.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.64% | -4,814.41% | -82.35% | -246.26% | -3,766.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.64% | -4,814.41% | -82.35% | -246.26% | -3,766.67% |
| EBIT | 36.64% | -4,932.83% | -82.35% | -246.26% | -3,766.67% |
| EBITDA | 37.59% | -5,300.32% | -78.70% | -- | -- |
| EPS Basic | 40.00% | -5,500.00% | -33.33% | -200.00% | -- |
| Normalized Basic EPS | 33.33% | -6,900.00% | -50.00% | -100.00% | -- |
| EPS Diluted | 40.00% | -5,500.00% | -33.33% | -200.00% | -- |
| Normalized Diluted EPS | 33.33% | -6,900.00% | -50.00% | -100.00% | -- |
| Average Basic Shares Outstanding | 5.40% | 4.05% | 36.66% | 46.45% | 43.69% |
| Average Diluted Shares Outstanding | 5.40% | 4.05% | 36.66% | 46.45% | 43.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |